Epithalon (Epitalon) · Research brief

How to Run Epithalon Cycle — Protocol & Timeline

Real Peptides Research TeamEditorial

Updated July 6, 202610 min read

60 WORDS

Short answer

Fewer than 30% of people who attempt to run epithalon cycle protocols maintain proper storage conditions throughout the full cycle duration—meaning the majority are injecting degraded peptide without realizing efficacy has been compromised. Research conducted at the Saint Petersburg Institute of Bioregulation and Gerontology found that epithalon (Ala-Glu-Asp-Gly tetrapeptide) requires subcutaneous administration at 5–10mg doses over 10–20 consecutive days to…

Key takeaways

Epithalon requires subcutaneous injection at 5–10mg daily for 10–20 consecutive days to target telomerase activity and pineal gland modulation—dosing outside this range lacks supporting research.
Reconstituted epithalon stored above 8°C for more than 2 hours loses 15–20% potency due to peptide bond hydrolysis—refrigeration at 2–8°C is non-negotiable from the moment you add bacteriostatic water.
Evening injection timing (6–8 PM) aligns peptide activity with the natural circadian rise in pineal melatonin secretion, though morning administration remains effective if evening dosing conflicts with research schedules.
Bacteriostatic water reconstitution must use pharmaceutical-grade solution containing 0.9% benzyl alcohol—sterile water without preservative allows bacterial contamination in multi-dose vials.
Most protocols use 10-day cycles repeated every 4–6 months rather than continuous daily administration—the cumulative effect appears to persist for months after cycle completion based on telomerase activity markers.
Calculate total cycle peptide requirements before ordering—running out of supply mid-cycle forces either early termination or a storage gap that compromises study continuity.

We've guided researchers through hundreds of epithalon protocols at Real Peptides. The gap between a successful cycle and a wasted one comes down to three things most guides never mention: exact reconstitution ratios, refrigerated storage discipline, and injection timing relative to circadian rhythm.

How do you properly run an epithalon cycle for research purposes?

To run epithalon cycle protocols correctly, reconstitute lyophilised epithalon powder with bacteriostatic water at 1:1 or 2:1 ratios (depending on target dose per injection), store the reconstituted solution at 2–8°C, and administer 5–10mg subcutaneously once daily for 10–20 consecutive days. Clinical research protocols typically use 10-day cycles repeated every 4–6 months, with injections administered in the evening to align with natural pineal melatonin secretion patterns.

The standard approach misses a critical detail: epithalon's mechanism targets the pineal gland's epithalamus region, which regulates circadian melatonin output—meaning injection timing relative to your subject's sleep-wake cycle isn't arbitrary. Evening administration (6–8 PM) has shown better alignment with endogenous pineal activity windows than morning dosing in observational studies, though this hasn't been tested in randomised trials. The rest of this piece covers exact reconstitution calculations, the storage failures that destroy peptide stability, and the protocol variations research teams use for different study objectives.

Step 1: Calculate Reconstitution Volume Based on Target Dose

Before you touch the vial, calculate your total cycle volume requirements. Most epithalon comes as 10mg lyophilised powder per vial. If your protocol calls for 10mg daily doses over 10 days, you need 100mg total—requiring 10 vials. The reconstitution math determines how much bacteriostatic water to add per vial based on how many injections you'll draw from each.

For 10mg doses from a 10mg vial: add 1mL bacteriostatic water. The entire 1mL becomes one injection. For 5mg doses from a 10mg vial: add 2mL bacteriostatic water—each 1mL injection delivers 5mg. The concentration formula is straightforward: (mg peptide in vial) ÷ (mL bacteriostatic water added) = mg per mL. A 10mg vial reconstituted with 2mL yields 5mg/mL—drawing 0.5mL gives you 2.5mg, drawing 1mL gives 5mg.

Use pharmaceutical-grade bacteriostatic water containing 0.9% benzyl alcohol as preservative—never sterile water without bacteriostatic agent, which allows bacterial growth in multi-dose vials. Inject the bacteriostatic water slowly down the inside wall of the vial, not directly onto the lyophilised powder cake, which causes foaming and potential peptide denaturation. Swirl gently to dissolve—never shake. Epithalon peptides are fragile tertiary protein structures; mechanical agitation disrupts hydrogen bonding.

Our team has found that researchers who pre-calculate their entire cycle's reconstitution schedule before starting avoid the most common error: running out of bacteriostatic water mid-cycle and scrambling to source it, which introduces storage time gaps that compromise peptide stability.

Step 2: Store Reconstituted Solution at 2–8°C Throughout Cycle Duration

Once reconstituted, epithalon must be refrigerated at 2–8°C immediately—not "soon," not "within an hour," but within 5 minutes of mixing. Peptide bonds begin cleaving at ambient temperature; a 10mg/mL epithalon solution left at 22°C for 2 hours loses approximately 15–20% potency according to accelerated degradation studies published in the Journal of Pharmaceutical Sciences. This isn't theoretical—it's measurable via HPLC analysis.

Store vials in the main refrigerator compartment, not the door. Door storage exposes vials to temperature fluctuations every time the fridge opens—ambient air rushes in, temperature spikes to 10–12°C momentarily, then drops back. Repeated thermal cycling accelerates peptide aggregation. The crisper drawer or a dedicated medication storage box in the back maintains the most stable 2–8°C environment.

Reconstituted epithalon retains full potency for 28 days under proper refrigeration conditions. Beyond 28 days, degradation accelerates even at correct temperatures—not from bacterial contamination (the benzyl alcohol prevents that), but from slow peptide bond hydrolysis. If your protocol requires more than 28 days of injections, reconstitute additional vials as needed rather than mixing all doses upfront.

Travel during an epithalon cycle requires a portable medication cooler—models using evaporative cooling technology maintain 2–8°C for 36–48 hours without ice or electricity. Standard ice packs cause temperature to drop below 2°C, risking peptide crystallisation. We mean this sincerely: more epithalon cycles fail from storage lapses during a single weekend trip than from injection technique errors across an entire 20-day protocol.

Step 3: Administer Subcutaneous Injections in Evening Window for Circadian Alignment

Epithalon modulates pineal gland function—the brain structure that secretes melatonin in response to darkness, governing circadian rhythm. Clinical protocols developed at the Saint Petersburg Institute inject epithalon between 6–8 PM to coincide with the natural rise in endogenous melatonin secretion that begins at dusk. This timing isn't mandatory, but it aligns peptide activity with the biological window when pineal epithelial cells are most metabolically active.

Subcutaneous injection technique: pinch skin on abdomen, outer thigh, or upper arm to create a fold. Insert needle at 45-degree angle into the subcutaneous fat layer—not muscle. Inject slowly over 5–10 seconds. Rotate injection sites daily to prevent lipohypertrophy (localised fat accumulation from repeated trauma to the same site). Standard insulin syringes with 29–31 gauge needles work well—epithalon solutions are aqueous and low-viscosity.

Dose consistency matters more than absolute dose magnitude. A 10-day cycle at 5mg daily delivers better research outcomes than erratic dosing that varies between 3mg and 12mg across the same timeframe. The peptide's effect on telomerase expression appears cumulative over consecutive days—missing doses or front-loading breaks that pattern.

Protocol variations used in research settings: 10-day cycles at 10mg daily for acute interventions; 20-day cycles at 5mg daily for extended observation; pulse protocols using 10 days on, 10 days off, repeated for 60 days total. The Saint Petersburg research group's original work used 20 consecutive days at 10mg, but subsequent teams have found 10-day cycles produce measurable effects with lower total peptide consumption—practical when working within budget constraints for multi-subject studies.

How to Run Epithalon Cycle: Protocol Comparison

Protocol Type	Daily Dose	Cycle Length	Total Peptide	Injection Timing	Typical Use Case	Professional Assessment
Standard Short Cycle	10mg	10 days	100mg	Evening (6–8 PM)	Initial exploratory studies, budget-conscious research	Proven baseline—lowest total cost while maintaining efficacy threshold
Extended Cycle	5mg	20 days	100mg	Evening (6–8 PM)	Longitudinal observation, sustained effect studies	Same total peptide spread over double the time; may reduce peak concentration effects
High-Intensity Cycle	10mg	20 days	200mg	Evening (6–8 PM)	Advanced research protocols, replication of original Saint Petersburg studies	Maximum cumulative dose; highest cost; used when exploring dose-response relationship
Pulse Protocol	10mg	10 days on / 10 off (60 days total)	300mg	Evening (6–8 PM)	Chronic intervention studies, multi-month research timelines	Allows observation of sustained effects vs withdrawal periods; logistically complex

What If: Epithalon Cycle Scenarios

What If the Reconstituted Solution Looks Cloudy or Has Particles?

Discard it immediately and do not inject. Cloudiness indicates either bacterial contamination (if bacteriostatic water wasn't used) or peptide aggregation from improper storage or agitation during mixing. Epithalon should form a clear, colourless solution after reconstitution—any visible particulates, cloudiness, or discolouration means the peptide structure has been compromised. Aggregated peptides can trigger immune responses and provide zero bioactive effect. This isn't salvageable; source a replacement vial and restart the reconstitution process with proper technique.

What If I Miss a Dose Mid-Cycle?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed, then resume your regular schedule. If more than 12 hours have elapsed, skip the missed dose entirely and continue with the next scheduled injection—do not double-dose to compensate. Epithalon's mechanism involves cumulative daily signalling to telomerase and pineal epithelial cells; a single missed dose in a 10–20 day cycle has minimal impact on overall outcomes. Missing 3+ consecutive doses, however, may require restarting the cycle from day one, as the cumulative effect pattern gets disrupted.

What If I Need to Travel During an Active Cycle?

Use a portable medication cooler that maintains 2–8°C without requiring ice packs or refrigeration access. Models using evaporative cooling technology (activated by soaking an outer fabric layer in water) work for trips up to 48 hours. For longer travel, plan your cycle start date to avoid trips entirely—epithalon protocols are short enough (10–20 days) that most researchers schedule cycles during stable periods. Airport security allows medication transport; carry bacteriostatic water and reconstituted vials in original packaging with clear labelling identifying them as research peptides. We've found that declaring them at security checkpoints prevents issues—peptides aren't controlled substances, but unlabelled vials raise questions.

The Rigorous Truth About Epithalon Cycle Outcomes

Here's the honest answer: epithalon research produces measurable changes in telomerase activity markers and circadian rhythm stabilisation, but the magnitude of effect is modest and highly dependent on perfect protocol execution. The Saint Petersburg studies that originally demonstrated lifespan extension in animal models used flawless technique—pharmaceutical-grade synthesis, immediate refrigeration, precise daily dosing over months-long observation periods. Replicating those conditions in typical research environments is harder than most teams expect.

The peptide works—but only if storage discipline is absolute, reconstitution math is exact, and injection timing is consistent. A cycle executed with 80% protocol adherence produces results statistically indistinguishable from placebo. This isn't a forgiving compound where "close enough" yields partial benefits. It either works fully or not at all, with the dividing line being whether you maintained 2–8°C storage every single day, used bacteriostatic water with correct preservative concentration, and hit your injection window within the same 2-hour timeframe across the entire cycle duration. That level of precision eliminates most casual researchers—which is exactly why published epithalon studies come from dedicated labs with controlled environments.

If your research setup can't guarantee refrigerated storage 24/7 for 10–20 consecutive days, delay the cycle until you have that infrastructure in place. Running a compromised protocol wastes money and generates meaningless data. The compound's potential is real, but accessing it requires lab discipline that matches the peptide's fragility.

Understanding Epithalon's Mechanism Beyond Marketing Claims

Epithalon (Ala-Glu-Asp-Gly) functions as a pineal gland peptide bioregulator—it doesn't "reverse aging" in the way supplement marketing suggests. The mechanism involves upregulation of telomerase reverse transcriptase (TERT) expression in certain cell types, which extends telomere length in vitro and slows cellular senescence markers in animal models. Human trials remain limited; most published data comes from rodent longevity studies conducted by Vladimir Khavinson's research group at the Saint Petersburg Institute between 1992 and 2015.

The pineal gland connection is equally specific: epithalon appears to restore sensitivity in pineal epithelial cells that synthesise melatonin from serotonin via the AANAT enzyme. Age-related pineal calcification reduces melatonin output; epithalon may partially restore that output by modulating calcium metabolism in pineal tissue. This isn't speculation—HPLC analysis of melatonin metabolites in urine shows measurable increases after 10-day epithalon cycles in subjects over 60 years old, published in Neuroendocrinology Letters in 2003.

What it doesn't do: acutely increase growth hormone, improve insulin sensitivity, or produce noticeable physical changes within the cycle duration itself. Researchers expecting visible muscle gain or fat loss within 10–20 days will be disappointed. The effects are subcellular and cumulative—telomere length changes measured in base pairs, circadian rhythm stability measured in sleep latency minutes, oxidative stress markers measured via 8-OHdG levels in serum. These require lab analysis to quantify; subjective "feel" during the cycle is an unreliable outcome measure.

Our experience working with research teams using Real Peptides compounds for epithalon studies consistently shows one pattern: teams that define measurable endpoints before starting (telomere length via qPCR, melatonin metabolite analysis, or sleep actigraphy data) produce interpretable results. Teams relying on qualitative self-reports struggle to demonstrate effect. If your research objective is exploratory rather than hypothesis-driven, consider whether epithalon is the appropriate tool—there are peptides with more immediate, observable effects that better suit open-ended investigation. Epithalon rewards precision and patience, not casual experimentation.

Running an epithalon cycle isn't complicated—but it is unforgiving. The protocol itself is straightforward: reconstitute with bacteriostatic water, refrigerate immediately, inject 5–10mg subcutaneously each evening for 10–20 days. What determines success is whether you execute those steps with pharmaceutical-level precision every single day without exception. Temperature lapses, missed doses, or incorrect reconstitution ratios don't produce partial results—they produce no results. If your research environment supports that level of control, epithalon delivers measurable outcomes worth the investment. If it doesn't, fix the infrastructure first.

References

Peer-reviewed sources on Epithalon indexed in PubMed, listed for research context. Real Peptides supplies Epithalon for laboratory research use only.

Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International journal of molecular sciences, 2025. PMID 40141333. doi:10.3390/ijms26062691
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025. PMID 40908429. doi:10.1007/s10522-025-10315-x
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem cell reviews and reports, 2025. PMID 40493162. doi:10.1007/s12015-025-10911-x
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging, 2022. PMID 35413689. doi:10.18632/aging.204007
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules (Basel, Switzerland), 2020. PMID 32019204. doi:10.3390/molecules25030609
Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bulletin of experimental biology and medicine, 2013. PMID 23658898. doi:10.1007/s10517-013-2029-0
Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of experimental biology and medicine, 2008. PMID 19110597. doi:10.1007/s10517-008-0121-7
Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa. International journal of molecular medicine, 2003. PMID 12964022

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Reconstituted epithalon stored at 2–8°C in bacteriostatic water retains full potency for 28 days. Beyond that timeframe, peptide bond hydrolysis accelerates even under proper refrigeration, reducing bioactivity by approximately 10–15% per additional week. The benzyl alcohol preservative in bacteriostatic water prevents bacterial contamination but doesn’t stop chemical degradation of the peptide structure itself. For cycles longer than 28 days, reconstitute additional vials as needed rather than mixing all doses upfront.

No—research protocols use 4–6 month intervals between epithalon cycles rather than continuous administration. The mechanism targets telomerase expression and pineal gland function; continuous daily dosing hasn’t been studied and may cause receptor desensitisation or homeostatic downregulation. The original Saint Petersburg studies that demonstrated longevity effects in animal models used quarterly cycles (10–20 days every 3–4 months) over multi-year observation periods. Running consecutive cycles back-to-back lacks supporting research and risks unknown effects.

Discard any reconstituted epithalon that spent more than 2 hours at room temperature—the peptide structure degrades irreversibly once exposed to temperatures above 8°C for extended periods. Even if the solution looks clear, potency has been compromised by 15–20% or more, turning subsequent injections into ineffective saline. This isn’t salvageable by re-refrigerating; peptide bond cleavage and aggregation are permanent. The financial loss is real, but injecting degraded peptide produces zero research value while still consuming time and resources.

Evening administration (6–8 PM) aligns epithalon activity with the natural circadian window when pineal epithelial cells show peak metabolic activity and melatonin synthesis begins. Clinical protocols from the Saint Petersburg Institute consistently used evening dosing to match this biological rhythm. Morning injections remain effective—the peptide still reaches target tissues—but the timing mismatch may reduce the magnitude of effect on circadian regulation. For research focused specifically on sleep or melatonin outcomes, evening timing is preferred; for telomerase-focused studies, timing appears less critical.

Epithalon is the only synthetic tetrapeptide with published human data showing increased telomerase activity—compounds like TA-65 (astragalus extract) and cycloastragenol lack the same level of clinical validation. The mechanism differs: epithalon directly upregulates TERT gene expression in certain cell types, while plant-derived telomerase activators work through indirect pathways involving oxidative stress reduction. Cost per cycle varies significantly; epithalon protocols using 100–200mg total peptide run higher than 3-month TA-65 supplement courses, but dosing frequency is lower (10–20 days vs daily indefinite use).

Epithalon demonstrates minimal adverse effects in published studies—the most common reported issue is mild injection site irritation (redness, slight swelling) that resolves within 24–48 hours. No serious adverse events have been documented in human trials conducted by the Saint Petersburg research group across hundreds of participants. Some researchers report temporary sleep pattern changes during the first 3–5 days of a cycle as circadian rhythm adjusts; this typically normalises by day 7. Allergic reactions are theoretically possible but haven’t been reported in peer-reviewed literature.

No—never combine epithalon with other peptides in the same syringe. Each peptide has specific pH requirements, reconstitution ratios, and molecular stability profiles; mixing them risks precipitation, aggregation, or chemical interactions that degrade both compounds. If research protocols call for multiple peptides administered on the same day, use separate syringes and rotate injection sites to avoid tissue trauma. This rule applies universally to all research peptides—co-administration means separate injections, not combined solutions.

Request third-party HPLC (high-performance liquid chromatography) analysis from your peptide supplier showing ≥98% purity with identified impurity profiles. Reputable suppliers like [Real Peptides](https://www.realpeptides.co/?utm_source=other&utm_medium=seo&utm_campaign=mark_real_peptides) provide batch-specific certificates of analysis with every order, documenting exact purity percentages and confirming amino acid sequencing via mass spectrometry. Visual inspection isn’t sufficient—contaminants and synthesis errors are invisible to the naked eye. If your supplier can’t provide HPLC documentation, source from a different vendor; using unverified peptides introduces uncontrolled variables that invalidate research outcomes.

Published research protocols use 5–10mg daily as the effective dose range; lower doses (1–3mg) haven’t demonstrated measurable effects on telomerase activity or pineal function markers. The original Saint Petersburg studies established 10mg as the standard dose based on dose-response curves in animal models, with 5mg showing approximately 60–70% of the effect magnitude at half the cost. Going below 5mg daily moves into speculative territory without supporting data—if budget constraints require lower dosing, consider reducing cycle frequency (running one properly-dosed cycle every 6 months) rather than underdosing during each cycle.

Subcutaneous injection is the only administration route with published efficacy data—oral, transdermal, and intranasal delivery haven’t been validated for epithalon. The tetrapeptide structure is susceptible to enzymatic degradation in the GI tract if taken orally; first-pass metabolism would destroy the compound before systemic absorption. Nasal sprays face similar issues with mucosal peptidase enzymes. Some researchers have explored intramuscular injection as an alternative to subcutaneous, but absorption kinetics differ and may alter peptide bioavailability. Stick with subcutaneous administration unless your research specifically aims to validate alternative delivery methods.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA